Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | F10 | P00742 | 3/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.31 |
| ▸ | LTA4H | P09960 | 1/20 | 0.30 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.30 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
| ▸ | SRC | P12931 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25016052 | 0.92 | KMT2A (0.33) | KMT2AF10MTNR1AMTNR1B | |
| SCHEMBL25015785 | 0.89 | F10 (0.42) | KMT2AF10 | |
| SCHEMBL25016848 | 0.89 | F10 (0.40) | KMT2AF10SRC | |
| SCHEMBL25016422 | 0.88 | RHEB (0.36) | KMT2A | |
| SCHEMBL25015750 | 0.86 | CCR2 (0.36) | KMT2AF10 | |
| SCHEMBL25015779 | 0.85 | F10 (0.44) | KMT2AF10 | |
| SCHEMBL25015813 | 0.83 | KMT2A (0.40) | KMT2AF10MTNR1AMTNR1BSRC | |
| SCHEMBL25016831 | 0.83 | F10 (0.44) | F10 | |
| SCHEMBL25016427 | 0.83 | F10 (0.42) | F10 | |
| SCHEMBL25017612 | 0.82 | F10 (0.41) | KMT2AF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230043159-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | DISC MEDICINE, INC. | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230043159-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | MMP7, MATR3, SPINT2 | KMT2A 1072/4885F10 1548/4885MTNR1A 1514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.